---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-005340"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:42:29.486872+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience Q2 revenue flat, cuts workforce; guides to 1-5% growth and 13-14% op margin

## Summary
- Q2 revenue flat at $29.2M; GAAP operating income $4.0M includes $4.9M litigation benefit.
- Adjusted operating income $3.1M vs $4.3M YoY; adjusted EPS $0.05 vs $0.06.
- Gross margin improved to 58% from 57%.
- Company discontinuing non-strategic products and cutting ~5% of global workforce.
- FY2022 guidance: 1-5% reported revenue growth; adjusted operating margin 13-14%.

## SEC filing metadata
- accession: 0001171843-22-005340
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184322005340/0001171843-22-005340-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184322005340/f8k_080422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-005340
- JSON: https://secwatch.observer/filing/0001171843-22-005340.json
- Plain text: https://secwatch.observer/filing/0001171843-22-005340.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.